RecruitingNot ApplicableNCT06524427

Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)

Robot-Assisted Versus Video-Assisted Lobectomy for Non-Small Cell Lung Cancer (RAVAR): A Multicenter, Open-Label, Randomized, Non-Inferiority Trial

Sponsor

Sun Yat-sen University

Enrollment

1,124 participants

Start Date

Aug 25, 2020

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

Video-assisted thoracic surgery (VATS) has been recommended by clinical guidelines as one of the preferred surgeries for early-stage non-small cell lung cancer (NSCLC) for many years. However, VATS has inherent drawbacks, so at the beginning of this century, robotic-assisted thoracoscopic surgery (RATS) was first applied for lung resection. In recent years, RATS has developed rapidly, but there are still many unsolved scientific problems in the field of RATS. Thus, a multicenter prospective randomized controlled trial was conducted with stage I-II NSCLC patients as the study subject and 5-year DFS as the primary endpoint to compare the short-term and long-term outcomes of RATS and VATS in the treatment of early-stage NSCLC.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing two minimally invasive surgical techniques for removing a lobe of the lung in patients with early-stage non-small cell lung cancer (NSCLC): robot-assisted surgery and video-assisted surgery. Both approaches use small incisions, but robots offer more precise instrument movement. Researchers want to determine which method leads to better outcomes. **You may be eligible if...** - You are between 18 and 80 years old - You have been clinically diagnosed with non-small cell lung cancer (adenocarcinoma, squamous cell, or other types) - Your tumor is early stage (up to 5 cm, with no large lymph node involvement) - Your overall health and organ function (blood pressure, lung capacity, liver, kidneys) are within acceptable ranges - You have not received chemotherapy, radiation, or targeted therapy before surgery **You may NOT be eligible if...** - You have received cancer treatment before surgery - You have had another cancer previously - Your lung opacity appears as pure or mostly "ground-glass" on CT scan - You have small cell lung cancer - You have previously had open chest surgery on the same side - You are pregnant or breastfeeding - You have severe lung scarring, heart disease, or a serious active infection Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURERobot-assisted lobectomy

Patients will receive robot-assisted lobectomy using Da Vinci surgical system

PROCEDUREVideo-assisted lobectomy

Patients will receive video-assisted lobectomy

Locations(23)

First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Gansu Provincial Hospital

Lanzhou, Gansu, China

The Second Hospital of Lanzhou University

Lanzhou, Gansu, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Shenzhen People's Hospital

Shenzhen, Guangdong, China

Shenzhen Third People's Hospital

Shenzhen, Guangdong, China

Guangxi Nanxishan Hospital

Guilin, Guangxi, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Wuhan Union Hospital

Wuhan, Hubei, China

Wuhan TongJi Hospital

Wuhan, Hubei, China

The General Hospital of Eastern Theater Command

Nanjing, Jiangsu, China

Jiangsu Cancer Institute & Hospital

Nanjing, Jiangsu, China

Jiangxi Provincial People's Hopital

Nanchang, Jiangxi, China

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Liaoning Tumor Hospital & Institute

Shenyang, Liaoning, China

Tang-Du Hospital

Xi'an, Shaanxi, China

Qilu Hospital of Shandong University

Jinan, Shandong, China

Qianfoshan Hospital

Jinan, Shandong, China

Shandong Provincial Hospital

Jinan, Shandong, China

The Affiliated Hospital of Qingdao University

Qingdao, Shandong, China

Sichuan Cancer Hospital and Research Institute

Chengdu, Sichuan, China

West China Hospital

Chengdu, Sichuan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06524427

Related Trials

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT034128771 location

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143207 locations

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

NCT056578739 locations

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137260 locations